Navigation Links
LX4211 for Diabetes Shown to Reduce Fasting and Post-Prandial Blood Sugar in Healthy Subjects
Date:9/13/2011

le metabolic effects in healthy subjects, together with the safety profile observed to date, suggest that LX4211 could be considered earlier in the diabetes treatment paradigm, perhaps including the potential treatment of pre-diabetes in patients with impaired glucose tolerance or impaired fasting glucose (IGT/IFG)."

About the Clinical Trial

The clinical trial was designed to assess the effect of different LX4211 dose schedules relative to meal time  in healthy subjects when taken as a single daily dose (400 mg) or a split dose (200 mg twice daily).  Subjects were randomized to LX4211 in an ordered sequence to assess the pharmacodynamic effects of different dosing times, ranging from 1 hour prior to meals to immediately prior to meals.  Pharmacodynamic effects, include urinary glucose excretion, fasting plasma glucose, insulin, PYY and GLP-1 (total and active) were assessed at multiple time points during the 12-day dosing period.

About Lexicon

Lexicon is a biopharmaceutical company focused on discovering breakthrough treatments for human disease.  Lexicon currently has four drug programs in mid-stage development for diabetes, irritable bowel syndrome, carcinoid syndrome and rheumatoid arthritis, all of which were discovered by Lexicon's research team.  Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets.  Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs.  For additional information about Lexicon and its programs, please visit www.lexpharma.com.

Safe Harbor Statement

This press release contains "forward-looking statements," including statements relating to Lexicon's clinical development of LX4211, including characterizations of the results of and projected timing o
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes
2. Phase 2 Trial of LX4211 Demonstrates Significant and Rapid Improvements in Multiple Parameters in Type 2 Diabetic Patients
3. Lexicon Presents Data Describing LX4211 Positive Phase 2 Clinical Results and Novel Mechanism of Action for Type 2 Diabetes
4. Lexicon Announces Positive Results from New Clinical Study of LX4211 in Type 2 Diabetes Patients
5. Lexicon Presents LX4211 Mechanism of Action Data at American Diabetes Association Meeting and Announces Commencement of Phase 2b Clinical Trial in Type 2 Diabetes
6. Lexicon Presents LX4211 Clinical Data at European Association for the Study of Diabetes Annual Meeting
7. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
8. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
9. The Heart, Diabetes, And Weight Loss Centers of New York Introduce the New Science of Metabolic Diagnosis and Weight Management
10. Isis Initiates Phase 1 Study of ISIS 325568 Targeting Glucagon Receptor to Treat Type 2 Diabetes
11. Diabetes Research Institute Invention Promotes Growth of Stem Cells into Insulin-Producing Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... BioPharmX Corporation (NYSE MKT: BPMX) a Silicon Valley-based ... chief executive officer and co-founder of BioPharmX, will present at ... place, September 8-10, 2015 at The St. Regis Hotel, ... scheduled to present on September 10 from 2:10 to 2:35 ... A live webcast of the presentation will be ...
(Date:9/2/2015)... 2, 2015 Tumultuous market conditions – including ... care M&A activity – have led more than half ... pharmaceutical sales reps. This marks the first time that ... the halfway point, according to the spring 2015 ... ZS . AccessMonitor™ aggregates ...
(Date:9/2/2015)... , Sept. 2, 2015  Kastle Therapeutics (Kastle), ... commercializing pharmaceuticals for diseases with high unmet medical ... executives to key commercial operating positions. ... President, Commercial; Sean was previously Global Marketing Director ... appointed as Director, Commercial Strategy and Analytics; Nick ...
Breaking Medicine Technology:Crossing the threshold: More than half of physicians restrict access to sales reps 2Crossing the threshold: More than half of physicians restrict access to sales reps 3Crossing the threshold: More than half of physicians restrict access to sales reps 4Crossing the threshold: More than half of physicians restrict access to sales reps 5Kastle Therapeutics Announces Key Additions to Commercial Leadership 2Kastle Therapeutics Announces Key Additions to Commercial Leadership 3
... , PLEASANTON, ... ), a world leader in device-based mechanical circulatory support therapies to save, ... in revenues from its Cardiovascular Division in fiscal 2009 led to a ... , For the year ended January 2, 2010 , revenues ...
... Jan. 28 A $3.5 million research ... implantable cardioverter defibrillators (ICDs) in patients at risk of death ... Healthcare Research and Quality and the American College of Cardiology, ... in cooperation with the National Heart, Lung, and Blood Institute, ...
Cached Medicine Technology:Thoratec Reports a 19 Percent Increase in Annual Revenues as Cardiovascular Division Revenues Increase 30 Percent in 2009 2Thoratec Reports a 19 Percent Increase in Annual Revenues as Cardiovascular Division Revenues Increase 30 Percent in 2009 3Thoratec Reports a 19 Percent Increase in Annual Revenues as Cardiovascular Division Revenues Increase 30 Percent in 2009 4Thoratec Reports a 19 Percent Increase in Annual Revenues as Cardiovascular Division Revenues Increase 30 Percent in 2009 5Thoratec Reports a 19 Percent Increase in Annual Revenues as Cardiovascular Division Revenues Increase 30 Percent in 2009 6Thoratec Reports a 19 Percent Increase in Annual Revenues as Cardiovascular Division Revenues Increase 30 Percent in 2009 7Thoratec Reports a 19 Percent Increase in Annual Revenues as Cardiovascular Division Revenues Increase 30 Percent in 2009 8Thoratec Reports a 19 Percent Increase in Annual Revenues as Cardiovascular Division Revenues Increase 30 Percent in 2009 9Thoratec Reports a 19 Percent Increase in Annual Revenues as Cardiovascular Division Revenues Increase 30 Percent in 2009 10Thoratec Reports a 19 Percent Increase in Annual Revenues as Cardiovascular Division Revenues Increase 30 Percent in 2009 11Thoratec Reports a 19 Percent Increase in Annual Revenues as Cardiovascular Division Revenues Increase 30 Percent in 2009 12Thoratec Reports a 19 Percent Increase in Annual Revenues as Cardiovascular Division Revenues Increase 30 Percent in 2009 13Thoratec Reports a 19 Percent Increase in Annual Revenues as Cardiovascular Division Revenues Increase 30 Percent in 2009 14Thoratec Reports a 19 Percent Increase in Annual Revenues as Cardiovascular Division Revenues Increase 30 Percent in 2009 15Thoratec Reports a 19 Percent Increase in Annual Revenues as Cardiovascular Division Revenues Increase 30 Percent in 2009 16Thoratec Reports a 19 Percent Increase in Annual Revenues as Cardiovascular Division Revenues Increase 30 Percent in 2009 17Thoratec Reports a 19 Percent Increase in Annual Revenues as Cardiovascular Division Revenues Increase 30 Percent in 2009 18Thoratec Reports a 19 Percent Increase in Annual Revenues as Cardiovascular Division Revenues Increase 30 Percent in 2009 19Thoratec Reports a 19 Percent Increase in Annual Revenues as Cardiovascular Division Revenues Increase 30 Percent in 2009 20Thoratec Reports a 19 Percent Increase in Annual Revenues as Cardiovascular Division Revenues Increase 30 Percent in 2009 21Thoratec Reports a 19 Percent Increase in Annual Revenues as Cardiovascular Division Revenues Increase 30 Percent in 2009 22Thoratec Reports a 19 Percent Increase in Annual Revenues as Cardiovascular Division Revenues Increase 30 Percent in 2009 23Thoratec Reports a 19 Percent Increase in Annual Revenues as Cardiovascular Division Revenues Increase 30 Percent in 2009 24AHRQ and American College of Cardiology Collaborate On Study of Implantable Cardioverter Defibrillators 2
(Date:9/2/2015)... ... September 02, 2015 , ... Ericson is a noted speaker ... for HCPro and Associate Director of Education for the Association for Clinical Documentation Improvement ... ICD-10 for CDI Boot Camps. She serves as a CDI subject matter expert for ...
(Date:9/2/2015)... Appleton, WI (PRWEB) , ... September 02, 2015 ... ... Midwest, Cypress Benefit Administrators is taking action after seeing a significant ... The TPA’s Argus Claim Review division has found many cases of OON ASCs ...
(Date:9/2/2015)... ... 2015 , ... The 2015 China Overseas Investment and Entrepreneurship ... conference will be hosted at five star Beijing Kunlun Hotel and Diaoyutai State ... feature leading EB-5 industry professionals and Chinese private equity partners looking for international ...
(Date:9/2/2015)... ... 02, 2015 , ... Amada Senior Care, premier provider of in-home care and ... Johnson County location. Amada franchise partners Mike and Mell Fleming came to the ... spent over 20 years in medical device sales while Mell spent over 30 years ...
(Date:9/2/2015)... ... September 02, 2015 , ... SonicSurg Innovations, ... market, announced today that more than 600 successful patient procedures have been performed ... Plus, nearly 70 of these procedures have been on triggering thumbs. , ...
Breaking Medicine News(10 mins):Health News:ezDI Names Noted CDI Educator Cheryl Ericson as Company’s Clinical Documentation Manager 2Health News:ezDI Names Noted CDI Educator Cheryl Ericson as Company’s Clinical Documentation Manager 3Health News:ezDI Names Noted CDI Educator Cheryl Ericson as Company’s Clinical Documentation Manager 4Health News:TPA Cracks Down on Forbidden Tactics Used by Out-of-Network Surgical Centers 2Health News:TPA Cracks Down on Forbidden Tactics Used by Out-of-Network Surgical Centers 3Health News:The 2015 China Overseas Investment and Entrepreneurship Summit (COIES) Announced 2Health News:Amada Senior Care Expands to Greater Kansas City 2Health News:Trigger Tome Surpasses 600 Successful Patient Procedures 2
... in lab tests, researchers say , FRIDAY, Feb. 26 ... after diagnosis, but researchers have identified an oncogene that ... Even more hopeful is that drugs that target this ... are undergoing tests with colon and lung cancers, said ...
... for autism, stroke and other conditions , FRIDAY, ... of children,s brains during reading discovered something rather unexpected: ... of white matter tracts in the brain, and the ... out words. , "This is the first evidence ...
... account, researcher says , FRIDAY, Feb. 26 (HealthDay News) ... for pregnant women and their unborn babies mean that ... diagnosed with gestational diabetes, a new study suggests. , ... women being diagnosed with gestational diabetes, the new measurements ...
... ... ... ... ...
... ... ... , , , ... ...
... , ... ... ... ...
Cached Medicine News:Health News:New Treatment Eyed for Deadly Pancreatic Cancer 2Health News:New Treatment Eyed for Deadly Pancreatic Cancer 3Health News:Reading Remediation Seems to Rewire the Brain 2Health News:Reading Remediation Seems to Rewire the Brain 3Health News:Twice as Many Women May Soon Be Diagnosed With Gestational Diabetes 2Health News:Pelosi, Obama Mislead on Abortion Funding in Health Care Bill 2Health News:Pelosi, Obama Mislead on Abortion Funding in Health Care Bill 3Health News:Pelosi, Obama Mislead on Abortion Funding in Health Care Bill 4Health News:Brain Cancer Survivor Will Cycle 4,170 Miles Across USA to 'Outsmart' Disease 2Health News:Brain Cancer Survivor Will Cycle 4,170 Miles Across USA to 'Outsmart' Disease 3Health News:Brain Cancer Survivor Will Cycle 4,170 Miles Across USA to 'Outsmart' Disease 4Health News:New Building at University of Michigan Health System Expands Eye Care, Unites Diabetes Researchers 2Health News:New Building at University of Michigan Health System Expands Eye Care, Unites Diabetes Researchers 3Health News:New Building at University of Michigan Health System Expands Eye Care, Unites Diabetes Researchers 4Health News:New Building at University of Michigan Health System Expands Eye Care, Unites Diabetes Researchers 5Health News:New Building at University of Michigan Health System Expands Eye Care, Unites Diabetes Researchers 6Health News:New Building at University of Michigan Health System Expands Eye Care, Unites Diabetes Researchers 7Health News:New Building at University of Michigan Health System Expands Eye Care, Unites Diabetes Researchers 8
... Osteopal V is a low viscosity bone ... in vertebroplasty. The bone cement is injected ... purposes. Osteopal V is used for the ... of zirconium dioxide is included in the ...
Based on the trusted Schaltenbrand-Wahren Atlas for Stereotaxy of the human brain, Atlasplan Software provides anatomical detail of the basal ganglia region of the brain and can help confirm target a...
... a comprehensive platform for standard neurosurgical ... to plan the optimal surgical path ... Combined with unique features such as ... planning tool, Neurosight becomes a very ...
3D Cranial is the most widely used surgical navigation software. Navigate with confidence and ease with our displayed Zone of Accuracy and several fully automated features. 3D Cranial offers seamless...
Medicine Products: